This contribution from HAS aims to provide guidance for, promote use of and increase confidence in health apps and smart devices, by supplying good practice guidelines for manufacturers and evaluators (evaluating bodies, consumer associations or medical professional organisations), who can use them for their own assessments.
In response to a demand from the Ministry of Health, HAS establishes guidelines on the place of Point-of-Care Tests (POCTs) in hepatitis B screening strategy. HAS defines the main conditions for the implementation of a combined use of hepatitis B virus (HBV), human immunodeficiency virus (HIV) and hepatitis C virus (HCV) POCTs in France and formulates recommendation for optimizing the efficiency of the POCTs testing, especially in medico-social and community settings.
The French National Authority for Health (HAS) is an independent public scientific authority with an overall mission of contributing to the regulation of the healthcare system by improving health quality and efficiency.
HAS produces recommendations (accelerated developed guidelines, best practice guidelines) and tools to facilitate their use by health professionals. The objective is to inform health professionals, patients and health care users of current best practices with the aim of improving the quality and security of care.
The French accreditation programme for hospitals aims to improve quality and safety of care through the generation of sustained changes in clinical practices and management. HAS standards address the hospital’s performance in specific areas; they specify requirements to ensure that patient care is provided in a safe manner and in a secure environment.
Haute Autorité de Santé strengthens its European and international commitment in its two core areas of activity: health technology assessment and improvement in the quality of care and patient safety.
The objective of an early dialogue is to provide scientific recommendations to pharmaceutical companies on how the last phase (usually phase III) of development of a drug should be conducted in order to enable the company to provide data that will satisfy the requirements of the health technology assessment (HTA).